Condition: Malignant Glioma of Brain · Astrocytoma · Malignant Astrocytoma · Sponsor: Henry Ford Health System
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.
This description comes directly from the study's public registry record.
Tobias Walbert, MD, PhD · 3139162723 · twalber1@hfhs.org
Nyati Shyam, PhD · 734-272-1751 · snyati1@hfhs.org
Always discuss trial participation with your own doctor first.
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05686798